


A solution for early HCC detection? Exactly.



Liver cancer is the fastest growing cause of cancer-related deaths in the United States¹

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, and if detected early, patient outcomes can be improved.^{2,3} Unfortunately, due to performance variability and low patient adherence, current surveillance methods may not do enough to improve early-stage detection.⁴⁻⁶



In fact, studies show, **<30% of patients adhere to surveillance testing.**⁴



Routine surveillance and early detection may improve HCC outcomes

Among at-risk patients who eventually developed liver cancer, **surveillance was linked with more than double the chance of early detection** versus no surveillance.^{2,3}

60% to 70% of patients experienced a 5-year survival with early-stage diagnosis and curative therapy.⁷

There is a new, highly sensitive solution that may change the future of HCC surveillance.

The Oncoguard® Liver solution— designed to help improve outcomes for more patients at risk of HCC

A simple, yet sophisticated blood test with high sensitivity^{8*}

The Oncoguard® Liver test uses a unique set of blood-based biomarkers carefully selected and validated for enhanced early-stage detection and actionable results. This convenient blood test was rigorously developed in patients with various disease etiologies, delivering a level of clarity and consistency you may not see with other surveillance methods.

For early-stage HCC

**82%
sensitivity**

at 87% specificity⁸

The Oncoguard® Liver solution offers a simple and convenient blood test:



Offers you the flexibility to integrate the test into your clinical workflow



One blood test in one location makes ongoing surveillance convenient



Simple qualitative results that are easy to interpret and actionable

Supporting adherence to surveillance with a flexible Patient Engagement Program[†]

Early detection is key to successful treatment of HCC. Unfortunately, patient adherence to HCC surveillance is estimated to be less than 30%.⁴ **The Oncoguard® Liver Patient Engagement Program** can help more patients stay on top of regular cancer testing and support the care you provide, with:



Support to explain the testing process



Liver cancer educational materials or brochure



HCC surveillance education



Outreach reminders

*When compared to other guideline-recommended blood tests.

†The Patient Engagement Program is flexible, allowing you and your patients to opt out of these programs at any time by calling our Customer Care Center at 1-844-870-8870.

The Oncoguard® Liver test offers a streamlined approach to HCC surveillance to help more patients access the vital testing they need.

Contact your representative or visit **OncoguardLiver.com/Provider** to learn more about integrating the Oncoguard® Liver solution into your workflow today.

References: 1. Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. *Cancer*. 2018;124(13):2785-2800 2. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med*. 2014;11(4):e1001624. doi: 10.1371/journal.pmed.1001624 3. Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. *Clin Gastroenterol Hepatol*. 2019;17(5):976-987.e4. doi: 10.1016/j.cgh.2018.10.031 4. Wolf E, Rich NE, Marrero JA, Parikh N, Singal AG. Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis [published online May 8, 2020]. *Hepatology*. 2020;10.1002/hep.31309. doi: 10.1002/hep.31309 5. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. *Gastroenterology*. 2018;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064 6. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. *Aliment Pharmacol Ther*. 2017;45(1):169-177. doi: 10.1111/apt.13841 7. Liver cancer survival rates. American Cancer Society. Revised January 29, 2021/ Accessed March 23, 2021. <https://www.cancer.org/cancer/liver-cancer/detection-diagnosis-staging/survival-rates.html> 8. Chalasani NP, Porter K, Bhattacharya A, et al. Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2021. doi: 10.1016/j.cgh.2021.08.010

EXACT SCIENCES CORPORATION
5505 Endeavor Lane | Madison, WI 53719

Oncoguard is a registered trademark of Exact Sciences Corporation in the US. All third-party marks—® and ™—are the property of their respective owners. ©2022 Exact Sciences Corporation. All rights reserved. OL.00086.HCP 5/2022

**EXACT
SCIENCES**